In Q2 2024, EcoR1 Capital held 45 positions worth $3.0B. They initiated 5 new positions and exited 30. Their largest holding was APLS ($445.3M). Portfolio value shrank -20.3% versus the prior quarter.
Frequently asked questions
What stocks did EcoR1 Capital own in Q2 2024?
EcoR1 Capital held 45 biotech stocks in their 13F portfolio in Q2 2024. Their top positions include APLS, PRTA, SRPT, ANAB, CRNX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was EcoR1 Capital's portfolio worth in Q2 2024?
EcoR1 Capital's tracked biotech portfolio was worth $3.0B across 45 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did EcoR1 Capital buy in Q2 2024?
EcoR1 Capital initiated 5 new positions in Q2 2024, including BCYC, TECX, RCKT, REPL, ATRA. They also increased 5 existing positions.
What did EcoR1 Capital sell in Q2 2024?
EcoR1 Capital fully exited 30 positions in Q2 2024, including ERAS, CGEM, BRCB, BEAM, ACET and 25 more. They also trimmed 3 existing positions.
Is EcoR1 Capital a biotech fund?
Growth-stage crossover fund investing in life sciences companies from late-stage private rounds through public equity. Named after the EcoR1 restriction enzyme, reflecting the firm's scientific roots. Focuses on platform technologies and novel therapeutic modalities.
Want AI analysis, insider signals, and catalyst overlays for EcoR1 Capital?
View latest EcoR1 Capital portfolio →